Lionco Pharmaceutical Group Co.,Ltd. (SHA:603669)
5.36
-0.24 (-4.29%)
Nov 13, 2026, 3:00 PM CST
SHA:603669 Revenue
Lionco Pharmaceutical Group had revenue of 102.72M CNY in the quarter ending September 30, 2026, a decrease of -6.83%. This brings the company's total for the last twelve months to 400.80M, down -6.92% year-over-year. In the year 2025, Lionco Pharmaceutical Group had annual revenue of 322.48M, down -15.09%. That makes Lionco Pharmaceutical Group the 26,596th largest company in the world by revenue and 4,653rd in China.
Revenue (ttm)
400.80M
Revenue Growth
-6.92%
P/S Ratio
9.53
Revenue / Employee
1.41M
Employees
284
Market Cap
3.82B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 322.48M | -57.30M | -15.09% |
| Dec 31, 2024 | 379.78M | 182.95M | 92.95% |
| Dec 31, 2023 | 196.83M | -92.43M | -31.95% |
| Dec 31, 2022 | 289.26M | -451.06M | -60.93% |
| Dec 31, 2021 | 740.33M | -260.67M | -26.04% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jinling Pharmaceutical Company | 3.17B |
| Jianmin Pharmaceutical Group | 3.12B |
| Luoxin Pharmaceuticals Group Stock | 2.23B |
| Fuan Pharmaceutical (Group) | 1.65B |
| Guizhou Sanli Pharmaceutical Co.,Ltd | 1.64B |
| Tianjin Lisheng Pharmaceutical | 1.27B |
| Hunan Hansen Pharmaceutical | 1.01B |
| LanZhou Foci Pharmaceutical | 941.70M |